# A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)

> **NCT03905330** · PHASE3 · COMPLETED · sponsor: **Mirum Pharmaceuticals, Inc.** · enrollment: 93 (actual)

## Conditions studied

- Progressive Familial Intrahepatic Cholestasis (PFIC)

## Interventions

- **DRUG:** Maralixibat
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03905330
- **Lead sponsor:** Mirum Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-09
- **Primary completion:** 2022-09-01
- **Final completion:** 2022-09-01
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2023-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03905330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03905330, "A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03905330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*